SVB Leerink

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

SVB Leerink Recent News

Why Did SVB Leerink Initiate Humana With Outperform?
While Humana Inc.’s (NYSE: HUM) stock already seems to price in the near-term concerns around rebounding medical costs and high COVID-19 costs, it offers an opportunity to gain exposure to “the post-COVID accelerating growth environment and associated 2022 inflection,” according to SVB Leerin
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday. What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company.
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers
ACADIA Pharmaceuticals Inc.
Cathie Wood Is Bullish On 908 Devices. An Analyst Makes A Case For The Stock
908 Devices Inc (NASDAQ: MASS) is seen as a high-growth life science tools company that analysts at SVB Leerink expect to “outperform” despite conservative 2021 guidance given by its management due to the current visibility.
Breaking Down Novavax's Coronavirus Vaccine Data: 2 Analysts Takes
Novavax, Inc. (NASDAQ: NVAX) shares were roaring higher Friday after the company reported topline results from the late-stage trial of its coronavirus vaccine candidate in the U.K.
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease.
SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline
Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were
Why SVB Leerink Is Bullish On Kinnate Biopharma
Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in an initia
Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine
Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, mRNA-1273, got FDA panel backing, in line with expectations, and is likely to be accorded emergency use authorization any
Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate
Pfizer Inc.
AstraZeneca Analyst Flags Lack Of Details In Interim COVID-19 Vaccine Data
AstraZeneca plc (NASDAQ: AZN) announced Monday interim Phase 3 data for its coronavirus vaccine candidate AZD1222 from studies conducted in the U.K.
Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential
Moderna Inc (NASDAQ: MRNA) announced Monday positive efficacy data from the first interim analysis of the Phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273.
Pfizer Analysts Raise Odds Of Success For Coronavirus Vaccine Candidate To 100%
Pfizer Inc. (NYSE: PFE) reported Monday with strong Phase 3 interim efficacy data for its coronavirus vaccine candidate.
What Pfizer's Coronavirus Vaccine Data Means For Moderna
Moderna Inc (NASDAQ: MRNA) shares were advancing strongly Monday after a rival vaccine developed by Pfizer Inc.
Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab
Biogen Inc (NASDAQ: BIIB) shares are retreating sharply after an Adcom committee recommende
Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline
Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in Novemb
Exact Sciences Rallies On 2 M&A Deals In Cancer Screening Market
Shares of cancer screening and diagnostics company EXACT Sciences Corporation (NASDAQ: EXAS) were rallying to a record high Tuesday after it announced two M&A transactions and third-quarter results.
Why Biogen's Fortunes Hinge On Aducanumab Approval
Biogen Inc (NASDAQ: BIIB) reported fairly solid third-quarter results Wednesday, sending its shares higher. 
Pfizer's COVID-19 Vaccine Candidate Primed For $3.5B In 2021 Sales: Analyst
The mRNA coronavirus vaccine in development by Pfizer Inc.
Moderna, Pfizer Have 2-Month Lead Over Coronavirus Vaccine Competitors: Analyst
The coronavirus vaccine race has two likely winners that have surged ahead in a crowded field, according to an SVB Leerink analyst.
Moderna Analyst On 4 Coronavirus Vaccine Program Risks
Moderna Inc (NASDAQ: MRNA) is one of the frontrunners in a crowded race to develop a vaccine against the novel coronavirus.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved